{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-25-000091","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.403275+00:00","generated_at":"2026-05-17T14:33:04.043039+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Acumen reports Q2 2025 net loss $41M, cash $166.2M; Phase 2 Alzheimer's topline expected late 2026","bullets":["Cash, equivalents, and marketable securities totaled $166.2M as of June 30, 2025, expected to fund operations into early 2027.","Net loss for Q2 2025 was $41.0M compared to $20.5M in Q2 2024, driven by higher R&D expenses.","Topline results from Phase 2 ALTITUDE-AD trial of sabirnetug for early Alzheimer's expected in late 2026.","Announced collaboration with JCR Pharmaceuticals for Enhanced Brain Delivery therapy; non-clinical data expected early 2026.","At AAIC 2025, presented data showing sabirnetug has 8,750-fold selectivity for toxic amyloid beta oligomers over monomers."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-25-000091","json":"https://secwatch.observer/filing/0001576885-25-000091.json","markdown":"https://secwatch.observer/filing/0001576885-25-000091.md","text":"https://secwatch.observer/filing/0001576885-25-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688525000091/0001576885-25-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688525000091/abos-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T14:33:04.043039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}